Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice

Behavioural Brain Research

Volumn 202, Issue 2, 2009, Pages 232-237

  Kalda, Anti ^a,b   Herm, Laura ^a   Rinken, Ago ^a   Zharkovsky, Alexander ^a   Chen, Jiang Fan ^b  

^a UNIVERSITY OF TARTU   (Estonia)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine A2A receptor antagonists; Dopamine partial agonists; L dopa induced dyskinesia; Terguride

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 (3 CHLOROSTYRYL)CAFFEINE; BENSERAZIDE; DOPAMINE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LEVODOPA; OXIDOPAMINE; SULFUR 35; TERGURIDE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CHRONIC DRUG ADMINISTRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORPUS STRIATUM; CROSS REACTION; DRUG EFFECT; DRUG POTENCY; DYSKINESIA; ENZYME BINDING; IN VITRO STUDY; LOCOMOTION; LOW DRUG DOSE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PARKINSONISM; PARTIAL AGONISM; PRIORITY JOURNAL; PROPHYLAXIS; PROVOCATION TEST; ROTATION; TREATMENT DURATION;

ANIMALS; ANTIPARKINSON AGENTS; BENZAZEPINES; CAFFEINE; CORPUS STRIATUM; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); LEVODOPA; LISURIDE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RANDOM ALLOCATION; RECEPTORS, ADENOSINE A2; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SULFUR RADIOISOTOPES;

EID: 67349159101     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.03.037     Document Type: Article

References (35)

1. Akai T., Yamaguchi M., Mizuta E., and Kuno S. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. Ann Neurol 33 (1993) 507-511
2. Aubert I., Guigoni C., Håkansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 (2005) 17-26
3. Baronti F., Mouradian M.M., and Conant K.E. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology 42 (1992) 1241-1243
4. Bennett J.P., and Piercey M.F. Pramipexole-a new dopamine agonist for the treatment of Parkinson's disease. J. Neurol. Sci. 163 (1999) 25-31
5. Bézard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9 (2003) 762-767
6. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20 (2005) 919-931
7. Carlsson A. Dopamine receptor agonists: intrinsic activity vs. state of receptor. J Neural Transm 57 (1983) 309-315
8. Cenci M.A., Lee C.S., and Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10 (1998) 2694-2706
9. Clark D., Hjorth S., and Carlsson A. Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm 62 (1985) 171-207
10. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J Neurol 252 Suppl. (2005) iv37-iv42
11. Ferré S., Fredholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20 (1997) 482-487
12. Filipová M., Filip V., Macek Z., Müllerová S., Marková J., Kás S., et al. Terguride in parkinsonism. A multicenter trial. Eur Arch Psychiatry Neurol Sci 237 (1988) 298-303
13. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A.E., Adler E.M., et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 14 (1993) 186-195
14. Franklin K., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press, San Diego
15. Fredduzzi S., Moratalla R., Monopoli A., Cuellar B., Xu K., Ongini E., et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci 22 (2002) 1054-1062
16. Fuxe K., Agnati L.F., Jacobsen K., Hillion J., Canals M., Torvinen M., et al. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 61 (2003) S19-S23
17. Henry B., Crossman A.R., and Brotchie J.M. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151 (1998) 334-342
18. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 20 Suppl. 11 (2005) S11-S16
19. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 58 Suppl. 1 (2002) S1-8
20. Jolkkonen J., Jenner P., and Marsden C.D. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Brain Res Mol Brain Res 32 (1995) 297-307
21. Jordan J., Johnson J.L., Regardie K., Chen R., Koprivica V., Tadori Y., et al. Dopamine D2 receptor partial agonist display differential or contrasting characteristics in membrane and cell-based assay of dopamine D2 receptor signaling. Prog Neuro-Psychoph 31 (2007) 348-356
22. Mailman R.B. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28 (2007) 390-396
23. Meller E., Bohmaker K., Namba Y., Friedhoff A.J., and Goldstein M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 31 (1987) 592-598
24. Metman L.V., Sethy V.H., Roberts J.R., Bravi D., Hoff J.I., Mouradian M.M., et al. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease. Mov Disord 9 (1994) 577-581
25. Milligan G. Principles: extending the utility of [35S]GTP gamma S binding assays. Trends Pharmacol Sci 24 (2003) 87-90
26. Obeso J.A., Olanow C.W., and Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23 Suppl. 10 (2000) S2-S7
27. Pacchetti C., Martignoni E., Bruggi P., Godi L., Aufdembrinke B., Miltenburger C., et al. Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo. Mov Disord 8 (1993) 463-465
28. Rinken A., Finnman U.B., and Fuxe K. Pharmacological characterization of dopamine-stimulated [35S]GTPgammaS binding in rat striatal membranes. Biochem Pharmacol 57 (1999) 155-162
29. Schapira A.H., Bezard E., Brotchie J., Calon F., Collingridge G.L., Ferger B., et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 5 (2006) 845-854
30. Schiffmann S.N., and Vanderhaeghen J.J. Ontogeny of gene expression of adenosine A2 receptor in the striatum: early localization in the patch compartment. J Comp Neurol 317 (1992) 117-128
31. Terasmaa A., Finnman U.B., Owman C., Ferré S., Fuxe K., and Rinken A. Modulation of [(35)S]GTPgammaS binding to Chinese hamster ovary cell membranes by D(2(short)) dopamine receptors. Neurosci Lett 280 (2000) 135-138
32. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367 (1971) 69-93
33. Wieland T., and Jakobs K.H. Measurement of receptor-stimulated guanosine 5′-O-(gamma-thio)triphosphate binding by G proteins. Method Enzymol 237 (1994) 3-13
34. Xiao D., Bastia E., Xu Y.H., Benn C.L., Cha J.H., Peterson T.S., et al. Forebrain adenosine A2A receptors contribute to L-3 4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci 26 (2006) 13548-13555
35. Yu L., Schwarzschild M.A., and Chen J.F. Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice. Neurosci Lett 393 (2006) 31-35